Natural history of malignant bone disease in renal cancer

Final results of an italian bone metastasis survey

Daniele Santini, Giuseppe Procopio, Camillo Porta, Toni Ibrahim, Sandro Barni, Calogero Mazzara, Andrea Fontana, Alfredo Berruti, Rossana Berardi, Bruno Vincenzi, Cinzia Ortega, Davide Ottaviani, Giacomo Carteni, Gaetano Lanzetta, Vladimir Virzì, Matteo Santoni, Nicola Silvestris, Maria Antonietta Satolli, Elena Collovà, Antonio Russo & 10 others Giuseppe Badalamenti, Stefano Luzi Fedeli, Francesca Maria Tanca, Vincenzo Adamo, Evaristo Maiello, Roberto Sabbatini, Alessandra Felici, Saverio Cinieri, Giuseppe Tonini, Sergio Bracarda

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC. Patients and methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed. Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P

Original languageEnglish
Article numbere83026
JournalPLoS One
Volume8
Issue number12
DOIs
Publication statusPublished - Dec 30 2013

Fingerprint

kidney neoplasms
bone diseases
Kidney Neoplasms
Bone Diseases
metastasis
Bone
bones
Neoplasm Metastasis
Bone and Bones
kidney cells
Renal Cell Carcinoma
carcinoma
zoledronic acid
Survival
Surveys and Questionnaires
Cells
therapeutics
acids

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Natural history of malignant bone disease in renal cancer : Final results of an italian bone metastasis survey. / Santini, Daniele; Procopio, Giuseppe; Porta, Camillo; Ibrahim, Toni; Barni, Sandro; Mazzara, Calogero; Fontana, Andrea; Berruti, Alfredo; Berardi, Rossana; Vincenzi, Bruno; Ortega, Cinzia; Ottaviani, Davide; Carteni, Giacomo; Lanzetta, Gaetano; Virzì, Vladimir; Santoni, Matteo; Silvestris, Nicola; Satolli, Maria Antonietta; Collovà, Elena; Russo, Antonio; Badalamenti, Giuseppe; Fedeli, Stefano Luzi; Tanca, Francesca Maria; Adamo, Vincenzo; Maiello, Evaristo; Sabbatini, Roberto; Felici, Alessandra; Cinieri, Saverio; Tonini, Giuseppe; Bracarda, Sergio.

In: PLoS One, Vol. 8, No. 12, e83026, 30.12.2013.

Research output: Contribution to journalArticle

Santini, D, Procopio, G, Porta, C, Ibrahim, T, Barni, S, Mazzara, C, Fontana, A, Berruti, A, Berardi, R, Vincenzi, B, Ortega, C, Ottaviani, D, Carteni, G, Lanzetta, G, Virzì, V, Santoni, M, Silvestris, N, Satolli, MA, Collovà, E, Russo, A, Badalamenti, G, Fedeli, SL, Tanca, FM, Adamo, V, Maiello, E, Sabbatini, R, Felici, A, Cinieri, S, Tonini, G & Bracarda, S 2013, 'Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey', PLoS One, vol. 8, no. 12, e83026. https://doi.org/10.1371/journal.pone.0083026
Santini, Daniele ; Procopio, Giuseppe ; Porta, Camillo ; Ibrahim, Toni ; Barni, Sandro ; Mazzara, Calogero ; Fontana, Andrea ; Berruti, Alfredo ; Berardi, Rossana ; Vincenzi, Bruno ; Ortega, Cinzia ; Ottaviani, Davide ; Carteni, Giacomo ; Lanzetta, Gaetano ; Virzì, Vladimir ; Santoni, Matteo ; Silvestris, Nicola ; Satolli, Maria Antonietta ; Collovà, Elena ; Russo, Antonio ; Badalamenti, Giuseppe ; Fedeli, Stefano Luzi ; Tanca, Francesca Maria ; Adamo, Vincenzo ; Maiello, Evaristo ; Sabbatini, Roberto ; Felici, Alessandra ; Cinieri, Saverio ; Tonini, Giuseppe ; Bracarda, Sergio. / Natural history of malignant bone disease in renal cancer : Final results of an italian bone metastasis survey. In: PLoS One. 2013 ; Vol. 8, No. 12.
@article{af2eaafa6bb94e169fd7833aeccf0bf6,
title = "Natural history of malignant bone disease in renal cancer: Final results of an italian bone metastasis survey",
abstract = "Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC. Patients and methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed. Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71{\%} of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P",
author = "Daniele Santini and Giuseppe Procopio and Camillo Porta and Toni Ibrahim and Sandro Barni and Calogero Mazzara and Andrea Fontana and Alfredo Berruti and Rossana Berardi and Bruno Vincenzi and Cinzia Ortega and Davide Ottaviani and Giacomo Carteni and Gaetano Lanzetta and Vladimir Virz{\`i} and Matteo Santoni and Nicola Silvestris and Satolli, {Maria Antonietta} and Elena Collov{\`a} and Antonio Russo and Giuseppe Badalamenti and Fedeli, {Stefano Luzi} and Tanca, {Francesca Maria} and Vincenzo Adamo and Evaristo Maiello and Roberto Sabbatini and Alessandra Felici and Saverio Cinieri and Giuseppe Tonini and Sergio Bracarda",
year = "2013",
month = "12",
day = "30",
doi = "10.1371/journal.pone.0083026",
language = "English",
volume = "8",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "12",

}

TY - JOUR

T1 - Natural history of malignant bone disease in renal cancer

T2 - Final results of an italian bone metastasis survey

AU - Santini, Daniele

AU - Procopio, Giuseppe

AU - Porta, Camillo

AU - Ibrahim, Toni

AU - Barni, Sandro

AU - Mazzara, Calogero

AU - Fontana, Andrea

AU - Berruti, Alfredo

AU - Berardi, Rossana

AU - Vincenzi, Bruno

AU - Ortega, Cinzia

AU - Ottaviani, Davide

AU - Carteni, Giacomo

AU - Lanzetta, Gaetano

AU - Virzì, Vladimir

AU - Santoni, Matteo

AU - Silvestris, Nicola

AU - Satolli, Maria Antonietta

AU - Collovà, Elena

AU - Russo, Antonio

AU - Badalamenti, Giuseppe

AU - Fedeli, Stefano Luzi

AU - Tanca, Francesca Maria

AU - Adamo, Vincenzo

AU - Maiello, Evaristo

AU - Sabbatini, Roberto

AU - Felici, Alessandra

AU - Cinieri, Saverio

AU - Tonini, Giuseppe

AU - Bracarda, Sergio

PY - 2013/12/30

Y1 - 2013/12/30

N2 - Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC. Patients and methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed. Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P

AB - Background: Bone metastasis represents an increasing clinical problem in advanced renal cell carcinoma (RCC) as disease-related survival improves. There are few data on the natural history of bone disease in RCC. Patients and methods: Data on clinicopathology, survival, skeletal-related events (SREs), and bone-directed therapies for 398 deceased RCC patients (286 male, 112 female) with evidence of bone metastasis were statistically analyzed. Results: Median time to bone metastasis was 25 months for patients without bone metastasis at diagnosis. Median time to diagnosis of bone metastasis by MSKCC risk was 24 months for good, 5 months for intermediate, and 0 months for poor risk. Median number of SREs/patient was one, and 71% of patients experienced at least one SRE. Median times to first, second, and third SRE were 2, 5, and 12 months, respectively. Median survival was 12 months after bone metastasis diagnosis and 10 months after first SRE. Among 181 patients who received zoledronic acid (ZOL), median time to first SRE was significantly prolonged versus control (n = 186) (3 months vs 1 month for control; P

UR - http://www.scopus.com/inward/record.url?scp=84893592812&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893592812&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0083026

DO - 10.1371/journal.pone.0083026

M3 - Article

VL - 8

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 12

M1 - e83026

ER -